https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

The global breast biopsy equipment market is currently on a parallel track of steady growth and rapid technological iteration. The increasing burden of breast cancer, the widespread awareness of early screening, and the advancement of minimally invasive diagnostic technologies are all driving this market to continuously expand and innovate.

The market size and growth momentum are showing a positive trend. According to analysis by Fortune Business Insights, the global market for breast biopsy equipment is expected to reach approximately $1.51 billion in 2025 and is projected to grow to $2.64 billion by 2034, with a compound annual growth rate (CAGR) of 6.5% over the forecast period. Another report estimates that the market size will be $2.7 billion in 2025 and is expected to reach $4.5 billion by 2035. The underlying logic for the growth is clear: the global incidence of breast cancer is continuously increasing. The World Health Organization reported in 2025 that approximately 670,000 people worldwide died from breast cancer in 2022. Governments and health organizations worldwide have vigorously promoted breast cancer screening programs, significantly increasing the detection rate of suspicious lesions, thereby driving the demand for biopsies. At the same time, the preferences of patients and clinicians for minimally invasive, precise, and rapid diagnosis are driving the penetration rate of advanced technologies such as vacuum-assisted biopsy (VAB) to continuously increase.

The regional markets exhibit a differentiated pattern. The North American region, with its mature healthcare system, high medical expenditures, and a tradition of early adoption of new technologies, will hold the leading position in the global market in 2025, with an estimated share ranging from 39% to 41.6%. The United States conducts over 1.1 million biopsy surgeries annually, and its strong infrastructure for mammography examinations and medical insurance support are the main driving forces. Europe is the second-largest market, accounting for approximately 27%-28% of the global share. Its centralized breast diagnosis units and strict screening systems support the market development. The Asia-Pacific region is regarded as the fastest-growing region, and it is expected to expand at a high CAGR. Improvements in medical infrastructure, increased awareness of breast cancer, and a large population base in countries such as China and India are key factors driving growth in this region. By 2025, the share of the Asia-Pacific region is expected to be approximately 23%.

The product and technology segments are each performing well. Among various biopsy devices, the vacuum-assisted biopsy (VAB) system stands out the most and is expected to capture the largest market share (approximately 35.4% - 48.9%). Its clinical advantages lie in being able to obtain sufficient and high-quality tissue samples with a single insertion, having a high diagnostic accuracy rate, and being capable of handling small lesions and calcifications effectively. From the perspective of guidance technology, ultrasound guidance dominates due to its real-time nature, lack of radiation, high cost-effectiveness, and good imaging performance for dense breast tissue (expected to account for 45.6% of the share in 2035). Digital biopsy systems (compared to analog systems) have occupied 58% of the installed equipment, and their adoption rate is still growing rapidly.

Frontier technological innovations shape the future. The future of the market is defined by several major trends: Firstly, the deep integration of artificial intelligence (AI) and intelligent navigation. AI algorithms are used to assist in image interpretation, automatically identify suspicious lesions, and even plan the optimal puncture path, which will significantly improve the accuracy of biopsy, reduce the operator's dependence, and increase the diagnostic efficiency by more than 18%. Secondly, the exploration and application of robot-assisted biopsy systems aim to achieve higher levels of operational stability and repeatability. Thirdly, multimodal image fusion and three-dimensional guidance, such as deeply integrating 3D tomography (Tomosynthesis) and MRI with the biopsy system, to provide a more three-dimensional positioning for complex lesions. Additionally, disposable, pre-assembled, and integrated biopsy kits are increasingly popular, as they simplify the operation process, reduce the risk of cross-infection, and improve the turnover efficiency of the operating room.

Challenges and opportunities coexist. The high cost of equipment, especially advanced digital systems and robotic platforms, remains the main obstacle to its widespread adoption in grassroots hospitals and emerging markets. The strict regulatory approval processes and constantly updated performance standards also prolong the product launch cycle. However, these challenges have also given rise to new opportunities, such as developing more cost-effective solutions, providing flexible financing or leasing models, and enhancing doctor training to improve accessibility to technology. Overall, the breast biopsy tool market is accelerating its evolution towards greater precision, intelligence, convenience, and inclusiveness.